Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis

NCT05450887 | Completed Phase 3

• 1 other identifier: ABDSP2021-III
• Study Type: interventional
• Target: 108
• Locations: 1 country
• Sites: 1

Brief Summary

Obecholic acid is a modified bile acid and Farnesoid X receptor (FXR) agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. Conventional therapy with obecholic acid will improve liver function of patients with (primary biliary cholangitis)PBC. The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on safety in participants with PBC.

Conditions

Primary Biliary Cholangitis

Outcome Measures

Primary Outcomes (1)

• Percentage of PBC patients reaching the compound endpoint after 12 months of treatment (Compound endpoint: alkaline phosphatase (ALP) < 1.67× Upper Limit of Normal(ULN), and ALP decrease ≥ 15% from baseline, and total bilirubin ≤ ULN )

  Compound endpoint: ALP \< 1.67× ULN, and ALP decrease ≥ 15% from baseline, and total bilirubin ≤ ULN

  up to 12 months

Secondary Outcomes (2)

• Absolute change and percentage change of ALP, total bilirubin, direct bilirubin, ALT, AST and GGT from baseline to Month 3, 6, 9 and 12

  up to 12 months

• Quality of life for PBC measure (PBC-40) score percentage change from baseline to Month 3, 6, 9 and 12

  up to 12 months

Study Arms (2)

OCA 5 mg titrated to 10 mg ± UDCA

EXPERIMENTAL

OCA 5 mg once daily for 3 months and then titrating up to 10 mg based on tolerability and response. Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA.

Drug: Obeticholic Acid Tablets（OCA）; Drug: UDCA

Placebo ± UDCA

PLACEBO COMPARATOR

Placebo once daily. Subjects receiving UDCA continued taking UDCA throughout the trial. If the subjects could not tolerate UDCA, they were not treated with UDCA.

Drug: UDCA; Drug: Placebo

Interventions

Obeticholic Acid Tablets（OCA） DRUG

Obeticholic Acid：Once a day (QD) by mouth (PO).

OCA 5 mg titrated to 10 mg ± UDCA

UDCA DRUG

UDCA：13\~15 mg/kg/day

OCA 5 mg titrated to 10 mg ± UDCA; Placebo ± UDCA

Placebo DRUG

Placebo：Once a day (QD) by mouth (PO).

Placebo ± UDCA

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 and ≤75 years；
• Definite PBC diagnosis, as demonstrated by the presence of ≥ 2 of the following 3 diagnostic factors: ① Indicators reflecting cholestasis such as elevated ALP；② Positive antimitochondrial antibody (AMA) or AMA-M2, or positive PBC-specific antibody (anti-GP210 and/or anti-SP100) if AMA negative；③ Liver biopsy consistent with PBC；
• At least 1 of the following qualifying biochemistry values: ① ALP ≥ 1.67x ULN ；② Total bilirubin \> ULN but \< 2x ULN；
• Taking UDCA for at least 6 months (stable dose for ≥ 3 months) prior to Day 0, or unable to tolerate UDCA (no UDCA for ≥ 3 months) prior to Day 0；
• Understand the study, comply with the study protocol, and voluntarily sign the informed consent form.

You may not qualify if:

• Patients who took obeticholic acid within 3 months prior to Day 0;
• Known hypersensitivity to obeticholic acid, ursodeoxycholic acid;
• History or presence of other concomitant liver diseases;
• Cirrhosis-related complications or end-stage liver disease manifestations;
• Serum creatinine (Cr) ≥ 1.5 × ULN and serum creatinine clearance \< 60 mL/min;
• Patients with severe pruritus or requiring systemic drug therapy within 2 months prior to Day 0;
• Patients with HIV or syphilis infection;
• Presence of diseases or physiological conditions that interfere with the absorption, distribution, metabolism or excretion of test drugs, such as inflammatory bowel disease and previous gastric bypass surgery;
• Presence of diseases that may cause non-hepatogenic ALP elevation, or diseases that may lead to a life expectancy of less than 2 years;
• Administration of the following drugs within 6 months prior to Day 0: azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil, pentoxifylline; fenofibrate or other fibrates; budesonide and other systemic corticosteroids; hepatotoxic drugs (including α-methyldopa, sodium valproate, isoniazid, nitrofurantoin, etc.);
• Administration of the following drugs within 12 months prior to Day 0: antibodies or immunotherapy against interleukins or other cytokines or chemokines;
• Patients with serious cardiovascular system, digestive system, respiratory system, urinary system, nervous system, mental illness, immunodeficiency disease, and judge by investigators that they are not suitable for participating in the trial;
• Other conditions that are not considered appropriate by the investigator.

Sponsors & Collaborators

• Nanjing Chia-tai Tianqing Pharmaceutical: lead

Study Sites (1)

Beijing Friendship Hospital

Beijing, 100050, China

Location

MeSH Terms

Conditions

Liver Cirrhosis, Biliary

Condition Hierarchy (Ancestors)

Cholestasis, Intrahepatic; Cholestasis; Bile Duct Diseases; Biliary Tract Diseases; Digestive System Diseases; Liver Diseases; Liver Cirrhosis; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2022
• First Posted: July 11, 2022
• Study Start: September 23, 2021
• Primary Completion: March 18, 2024
• Study Completion: April 9, 2024
• Last Updated: July 11, 2024

Record last verified: 2024-07

Locations

CN (1)